Abstract 5561: 20(S)-Protopanaxadiol-aglycone downregulates full-length and ligand-independent splice variants of androgen receptor

The study provided evidence that ginsenoside 20(S)-protopanaxadiol-aglycone (PPD) effectively downregulated both full-length and ligand-independent splice variants of the androgen receptor in prostate cancer cells. This downregulation was achieved through proteasome-mediated degradation and resulted in reduced tumor growth and decreased expression of prostate-specific antigen. The findings suggested that PPD could be a promising chemopreventive agent for prostate cancer, particularly due to its ability to target androgen receptor signaling, which is crucial in prostate cancer development and progression. The study highlighted the potential of PPD for further development in prostate cancer prevention and treatment.